Amicus Therapeutics (NASDAQ: FOLD) and Evoke Pharma (NASDAQ:EVOK) are both pharmaceuticals – nec companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations and institutional ownership.

Insider & Institutional Ownership

12.9% of Evoke Pharma shares are owned by institutional investors. 3.4% of Amicus Therapeutics shares are owned by company insiders. Comparatively, 20.0% of Evoke Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Amicus Therapeutics and Evoke Pharma’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Amicus Therapeutics $4.96 million 421.04 -$200.04 million ($1.83) -6.86
Evoke Pharma N/A N/A -$10.74 million ($0.94) -3.02

Evoke Pharma has higher revenue, but lower earnings than Amicus Therapeutics. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Evoke Pharma, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Amicus Therapeutics and Evoke Pharma, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amicus Therapeutics 0 1 6 0 2.86
Evoke Pharma 0 1 6 0 2.86

Amicus Therapeutics presently has a consensus price target of $18.07, suggesting a potential upside of 43.88%. Evoke Pharma has a consensus price target of $8.86, suggesting a potential upside of 211.87%. Given Evoke Pharma’s higher probable upside, analysts clearly believe Evoke Pharma is more favorable than Amicus Therapeutics.

Profitability

This table compares Amicus Therapeutics and Evoke Pharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Amicus Therapeutics -1,092.37% -63.54% -23.46%
Evoke Pharma N/A -167.16% -80.56%

Risk & Volatility

Amicus Therapeutics has a beta of 1.79, suggesting that its stock price is 79% more volatile than the S&P 500. Comparatively, Evoke Pharma has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500.

Summary

Evoke Pharma beats Amicus Therapeutics on 6 of the 10 factors compared between the two stocks.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc. is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. Its pipeline also includes SD-101, which is a product candidate in late-stage development, as a potential first-to-market therapy for the chronic, rare connective tissue disorder Epidermolysis Bullosa (EB). It is also leveraging its Chaperone-Advanced Replacement Therapy (CHART) platform technologies to develop ERT products for Pompe disease, Fabry disease, and potentially other lysosomal storage disorders (LSDs). The Company is also investigating preclinical and discovery programs in other rare and devastating diseases, including cyclin-dependent kinase-like 5 (CDKL5) deficiency.

Evoke Pharma Company Profile

Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. EVK-001 is a formulation of Metoclopramide drug, designed to provide systemic delivery of metoclopramide through intranasal administration. The Company has evaluated EVK-001 in a multicenter, randomized, double-blind, placebo-controlled parallel group, dose-ranging Phase IIb clinical trial. The Company has commenced a Phase III clinical trial of EVK-001 in female patients with symptoms associated with acute and recurrent diabetic gastroparesis. The Phase III clinical trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy, safety and population pharmacokinetics of EVK-001 in adult females.

Receive News & Stock Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related stocks with our FREE daily email newsletter.